ZNF219

Across TCGA pan-cancer cohorts, ZNF219 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ZNF219’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ZNF219 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF219 is over-expressed in tumor, although a few such as LUAD and BLCA show the opposite, repressed pattern.

LIHC, LUAD, and BLCA are the cancer types where ZNF219 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF219 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+2.185	<.001	9	view →
LUAD	All	II,III,IV	−1.216	<.001	8	view →
BLCA	All	III,IV	−0.787	.001	8	view →
COAD	Male	All	−0.676	<.001	7	view →
BRCA	All	II,III,IV	−1.315	<.001	6	view →
READ	All	All	−0.828	.010	6	view →
CHOL	Male	All	+2.615	<.001	5	view →
KICH	Female	II,III,IV	+1.405	<.001	4	view →
THCA	Male	III,IV	−0.967	.007	4	view →
KIRP	All	IV	+1.064	.010	2	view →
PRAD	All	All	−0.970	<.001	2	view →
UCEC	All	All	−0.496	.033	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ZNF219–LIHC

Open the LIHC breakdown →